Opportunistic mycosis

Summary

Opportunistic mycosis (MONDO:0002312) is a disease (an umbrella term covering 12 Mondo subtypes). A subtype of fungal infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 12 Mondo subtypes

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	opportunistic mycosis
Mondo ID	MONDO:0002312
DOID	DOID:2473
SNOMED CT	78999002
UMLS	C0029119
MedGen	508004
Is cancer (heuristic)	no

Also known as: opportunistic systemic mycoses

Disease family

This is a subtype of fungal infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › opportunistic mycosis

Related subtypes (17): cutaneous mycosis, systemic mycosis, fungal esophagitis, fungal gastritis, fungal lung infectious disease, Pneumocystis infectious disease, sporotrichosis, fungal meningitis, fungal myositis, scedosporiosis, fungal infection of eye, mycotic endocarditis, mycotoxicosis, alternariosis, invasive scopulariopsis infection, emergomycosis, fungal discitis

Subtypes (12): phaeohyphomycosis, candidiasis, maple bark strippers’ lung, aspergillosis, cryptococcosis, geotrichosis, microsporidiosis, fusariosis, pneumocystosis, Zygomycosis, opportunistic systemic mycosis, hyalohyphomycosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.